Literature DB >> 30123579

Potential clinical benefits of cell therapy in coronary heart disease: an update.

Vincenzo Grimaldi1,2, Alberto Zullo2,3, Francesco Donatelli4,5, Francesco Paolo Mancini2, Francesco Cacciatore4,5,6,7, Claudio Napoli1,8.   

Abstract

Cell therapy is a central issue of regenerative medicine and is raising a growing interest in the scientific community, but its full therapeutic potential in coronary heart disease (CHD) has not been reached yet. Several different methods, cell types, delivery routes, and supporting techniques have been attempted and improved to elicit cardiac regeneration in CHD, but only some of them showed a really convincing potential for the use in clinical practice. Here we provide an update on approaches and clinical trials of cell therapy applied to CHD, which are ongoing or that have been realized in the last 5 years. Moreover, we discuss the evidence collected so far in favor or against the validity of stem cell therapy for CHD. In particular, we review and comment the recent advances in cell therapy applied to CHD, the most promising cell types, delivery strategies, biochemical and engineering techniques that have been adopted in this context.

Entities:  

Keywords:  Cell therapy; clinical trials; coronary heart disease (CHD); progenitor cells; regenerative medicine; stem cells

Year:  2018        PMID: 30123579      PMCID: PMC6081359          DOI: 10.21037/jtd.2018.04.149

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  71 in total

Review 1.  Stem cells in the umbilical cord.

Authors:  Mark L Weiss; Deryl L Troyer
Journal:  Stem Cell Rev       Date:  2006       Impact factor: 5.739

Review 2.  Skeletal muscle stem cells.

Authors:  Margaret Buckingham; Didier Montarras
Journal:  Curr Opin Genet Dev       Date:  2008-07-30       Impact factor: 5.578

3.  Exosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction.

Authors:  Romain Gallet; James Dawkins; Jackelyn Valle; Eli Simsolo; Geoffrey de Couto; Ryan Middleton; Eleni Tseliou; Daniel Luthringer; Michelle Kreke; Rachel R Smith; Linda Marbán; Bijan Ghaleh; Eduardo Marbán
Journal:  Eur Heart J       Date:  2017-01-14       Impact factor: 29.983

4.  Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes.

Authors:  Christopher R Cogle; Elizabeth Wise; Amy M Meacham; Claudia Zierold; Jay H Traverse; Timothy D Henry; Emerson C Perin; James T Willerson; Stephen G Ellis; Marjorie Carlson; David X M Zhao; Roberto Bolli; John P Cooke; Saif Anwaruddin; Aruni Bhatnagar; Maria da Graca Cabreira-Hansen; Maria B Grant; Dejian Lai; Lem Moyé; Ray F Ebert; Rachel E Olson; Shelly L Sayre; Ivonne H Schulman; Raphael C Bosse; Edward W Scott; Robert D Simari; Carl J Pepine; Doris A Taylor
Journal:  Circ Res       Date:  2014-08-18       Impact factor: 17.367

5.  Three specific antigens to isolate endothelial progenitor cells from human liposuction material.

Authors:  Gudrun Hager; Wolfgang Holnthoner; Susanne Wolbank; Anna-Maria Husa; Kathrin Godthardt; Heinz Redl; Christian Gabriel
Journal:  Cytotherapy       Date:  2013-11       Impact factor: 5.414

Review 6.  Cell therapy for cardiac repair--lessons from clinical trials.

Authors:  Atta Behfar; Ruben Crespo-Diaz; Andre Terzic; Bernard J Gersh
Journal:  Nat Rev Cardiol       Date:  2014-03-04       Impact factor: 32.419

7.  mir-17-92 cluster is required for and sufficient to induce cardiomyocyte proliferation in postnatal and adult hearts.

Authors:  Jinghai Chen; Zhan-Peng Huang; Hee Young Seok; Jian Ding; Masaharu Kataoka; Zheng Zhang; Xiaoyun Hu; Gang Wang; Zhiqiang Lin; Si Wang; Willam T Pu; Ronglih Liao; Da-Zhi Wang
Journal:  Circ Res       Date:  2013-04-10       Impact factor: 17.367

8.  One-year follow-up of intracoronary stem cell delivery on left ventricular function following ST-elevation myocardial infarction.

Authors:  Jay H Traverse; Timothy D Henry; Carl J Pepine; James T Willerson; Stephen G Ellis
Journal:  JAMA       Date:  2014-01-15       Impact factor: 56.272

9.  Combined intramyocardial delivery of human pericytes and cardiac stem cells additively improves the healing of mouse infarcted hearts through stimulation of vascular and muscular repair.

Authors:  Elisa Avolio; Marco Meloni; Helen L Spencer; Federica Riu; Rajesh Katare; Giuseppe Mangialardi; Atsuhiko Oikawa; Iker Rodriguez-Arabaolaza; Zexu Dang; Kathryn Mitchell; Carlotta Reni; Valeria V Alvino; Jonathan Rowlinson; Ugolini Livi; Daniela Cesselli; Gianni Angelini; Costanza Emanueli; Antonio P Beltrami; Paolo Madeddu
Journal:  Circ Res       Date:  2015-03-23       Impact factor: 17.367

Review 10.  Inhibition of Myocardial Ischemia/Reperfusion Injury by Exosomes Secreted from Mesenchymal Stem Cells.

Authors:  Heng Zhang; Meng Xiang; Dan Meng; Ning Sun; Sifeng Chen
Journal:  Stem Cells Int       Date:  2016-04-26       Impact factor: 5.443

View more
  1 in total

Review 1.  Immunomodulatory Effect of Adipose-Derived Stem Cells: The Cutting Edge of Clinical Application.

Authors:  Simona Ceccarelli; Paola Pontecorvi; Eleni Anastasiadou; Claudio Napoli; Cinzia Marchese
Journal:  Front Cell Dev Biol       Date:  2020-04-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.